The Radiopharmaceutical Therapy and Companion Diagnostics Lab, under the direction of Daniel A. Pryma, MD, operates in close collaboration with the Radiological Chemistry and Biology Lab.
The primary focus of the lab is preclinical development and testing of novel therapeutic radiopharmaceuticals, particularly alpha emitters, along with associated companion diagnostics with the overarching goal of translation to human use.
The Radiopharmaceutical Therapy and Companion Diagnostics Lab and the Radiological Chemistry and Biology Lab are co-located in space design to support radionuclide-related research. This creates considerable synergy between the groups, and between the radionuclide-related research labs and the PET Center.
Daniel Pryma, MD